New Mobile Application Helps Clinical Research Associates Improve Efficiency, Optimize Clinical Development Process
Oracle Health Sciences today introduced Oracle Health Sciences Mobile Clinical Research Associate, which uses the power of mobile applications to help life sciences organizations compress clinical study cycle times and reduce costs by improving site monitoring efficiency and clinical research associate (CRA) productivity.
The mobile app, designed specifically for field use, is integrated with Oracle’s Siebel Clinical Trial Management System and Oracle Health Sciences Clinical Development Analytics to provide CRAs with real-time access to essential clinical trial information, decision support data, and comprehensive trip reports in either offline or connected modes.
Site-at-a-glance capabilities provide study site performance indicators in a single view so CRAs have up-to-date site progress information at their fingertips, enabling more efficient, proactive planning and more productive site visits.
Study and site alerts notify CRAs of key milestones, activities and potential problems for the study sites they are monitoring, enabling them to respond quickly to emerging issues.
The solution’s study site check-in feature automatically captures traveling CRAs’ site check-in details via geo-location capabilities and incorporates the information into the trip report, streamlining documentation for regulatory compliance.
Oracle Health Sciences Mobile Clinical Research Associate runs natively on iOS and is now available for Apple iPhone or Apple iPad via the Apple iTunes Store.
“With the increased pressure to reduce the time and cost of clinical trials, organizations need to optimize efficiency at every level. Unfortunately, despite the labor-intensive and critical role CRAs perform, most are still using traditional and antiquated tools to do their job. Oracle Health Sciences Mobile Clinical Research Associate is designed specifically to help CRAs improve productivity and lighten their load by enabling them to manage their responsibilities using a single mobile device,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.